Last reviewed · How we verify
NCT05850234: DURGA-1
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recruiting now
Phase 1, PHASE2
Last updated 6 April 2026
What this trial tests
Phase 1, PHASE2 trial testing AZD0120 in Relapsed/Refractory Multiple Myeloma in 182 participants. Currently enrolling.
Timeline
20 July 2023
Primary endpoint
31 August 2027
31 August 2027
14 November 2028
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 182 |
| Start date | 20 July 2023 |
| Primary completion | 31 August 2027 |
| Estimated completion | 14 November 2028 |
| Sites | 36 locations across United States |
Drugs / interventions tested
- AZD0120 — full drug profile →
Conditions studied
- Relapsed/Refractory Multiple Myeloma — all drugs for Relapsed/Refractory Multiple Myeloma →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Relapsed/Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multiple myeloma: signaling pathways and targeted therapy.
Lu Q, Yang D, Li H, Niu T, et al · · 2024 · cited 50× · PMID 38961036 · DOI 10.1186/s43556-024-00188-w -
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF, Dhakal B. · · 2023 · cited 14× · PMID 37507805 · DOI 10.1186/s13045-023-01479-5 -
Updates on CAR T cell therapy in multiple myeloma.
Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, et al · · 2024 · cited 10× · PMID 39261906 · DOI 10.1186/s40364-024-00634-5 -
Mapping the cancer surface proteome in search of target antigens for immunotherapy.
Di Meo F, Kale B, Koomen JM, Perna F. · · 2024 · cited 8× · PMID 39068512 · DOI 10.1016/j.ymthe.2024.07.019 -
CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.
Geng C, Chen W, Zhu HH. · · 2026 · PMID 41975476 · DOI 10.1186/s13045-026-01793-8
Verify or expand the search:
- PubMed search for NCT05850234
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AZD0120
Trials testing the same drug.
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
- NCT07350837 — CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants · EARLY_PHASE1 · recruiting
- NCT07295847 — A Study of AZD0120 in Autoimmune Diseases · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07073547 — A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharma · Phase 1 · recruiting
Other recruiting trials for Relapsed/Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT07493135 — A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT07509086 — IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia · Phase 2 · recruiting
- NCT06730256 — A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
- NCT06669247 — A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants · Phase 1, PHASE2 · recruiting
- NCT06718270 — a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05850234 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05850234.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing